SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Furiex Pharmaceuticals, Inc. Buyout
01 Maio 2014 - 4:37PM
Business Wire
Law office of Brodsky & Smith, LLC announces that it is
investigating potential claims against the Board of Directors of
Furiex Pharmaceuticals, Inc. (“Furiex” or the “Company”)
(Nasdaq:FURX) relating to the proposed acquisition by Forest
Laboratories, Inc.
Click here to learn more about the investigation
http://brodsky-smith.com/749-furx-furiex-pharmaceuticals-inc.html,
or call: 877-534-2590. There is no cost or obligation to you.
Under the terms of the transaction, Furiex shareholders will
receive only $95.00 in cash and a Contingent Value Right of up to
$30.00 in cash, that may be payable based upon the FDA status of
eluxadoline, for each share of Furiex stock they own. The
investigation concerns possible breaches of fiduciary duty and
other violations of state law by the Board of Directors of Furiex
for not acting in the Company’s shareholders’ best interests in
connection with the sale process. The transaction may undervalue
Furiex and is below the premium paid in comparable transactions.
For example, Furiex stock traded at $113.55 on February 5, 2014 and
an analyst has set a $140.00 per share price target on Furiex.
If you own shares of Furiex common stock and wish to discuss the
legal ramifications of the investigation, or have any questions,
you may e-mail or call the law office of Brodsky & Smith, LLC
who will, without obligation or cost to you, attempt to answer your
questions. You may contact Jason L. Brodsky, Esquire or Evan J.
Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite
602, Bala Cynwyd, PA 19004, by e-mail at
investorrelations@brodsky-smith.com, by visiting
http://brodsky-smith.com/749-furx-furiex-pharmaceuticals-inc.html,
or calling toll free 877-LEGAL-90.
Brodsky & Smith, LLC is a litigation law firm with extensive
expertise representing shareholders throughout the nation in
securities and case action lawsuits. The attorneys at Brodsky &
Smith have been appointed by numerous courts throughout the country
to serve as lead counsel in class actions and successfully
recovered millions of dollars for our clients and shareholders.
Attorney advertising. Prior results do not guarantee a similar
outcome.
Brodsky & Smith, LLCJason L. Brodsky, EsquireEvan J. Smith,
Esquire877-LEGAL-90investorrelations@brodsky-smith.comhttp://brodsky-smith.com/749-furx-furiex-pharmaceuticals-inc.html
(MM) (NASDAQ:FURX)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
(MM) (NASDAQ:FURX)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024